Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Ayalew TefferiTiziano BarbuiPublished in: American journal of hematology (2023)
At the present time, we do not consider a drug-induced reduction in JAK2V617F allele burden, which is often incomplete and seen not only with peg-IFN but also with ruxolitinib and busulfan, as an indicator of disease-modifying activity, unless accompanied by cytogenetic and independently-verified morphologic remission. Accordingly, we do not use the specific parameter to influence treatment choices. The current review also includes specific treatment strategies in the context of pregnancy, splanchnic vein thrombosis, pruritus, perioperative care, and post-PV MF.
Keyphrases
- drug induced
- liver injury
- healthcare
- palliative care
- pulmonary embolism
- immune response
- cardiac surgery
- quality improvement
- dendritic cells
- preterm birth
- rheumatoid arthritis
- adverse drug
- pregnancy outcomes
- ulcerative colitis
- allogeneic hematopoietic stem cell transplantation
- replacement therapy
- electronic health record
- health insurance
- affordable care act
- chronic pain